The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.

An international team of researchers, led by the University of Glasgow, hopes to find new ways to target opioid addiction ...

Irritable bowel syndrome (IBS) is a common digestive disorder with unclear causes, affecting about 10% of the global population. Researchers have now discovered that opioid delta-receptor agonists may ...

A new non-opioid painkiller, suzetrigine , has just been approved by the US drug regulator, the FDA. It is the first non-opioid painkiller the agency ...

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, ...

Using an innovative and recently validated animal model of IBS, the researchers showed that opioid delta-receptor agonists can ameliorate stress-induced IBS symptoms by acting on the insular cortex of ...

The FDA has approved suzetrigine, a groundbreaking non-opioid painkiller that targets pain at its source, offering a safer, ...

President Donald Trump's plan to impose tariffs on goods from Mexico, Canada and China is partly aimed at combating the ...

Last week’s settlement that would see Purdue Pharma and its owners, the Sackler family, pay $7.4 billion to resolve lawsuits filed by state and local governments across the country is ...

1 Department of Anesthesiology and Pediatric Clinical Pharmacology Laboratory ... chronic pain or had received opioids within the previous 24 h; 6) patients or guardians refusing participation in the ...

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

MONTREAL - The death of a Quebec teen who was poisoned from a synthetic opioid should raise alarm bells for authorities to do more to prevent similar tragedies.